A Second Laser Gets FDA-Cleared for Mild to Severe Acne

By ·
A Second Laser Gets FDA-Cleared for Mild to Severe Acne featured image
Getty Images / Image Used for Illustrative Purposes Only

More good news for the millions of acne sufferers searching for a solution as the Food and Drug Administration has cleared a second laser to treat mild to severe acne vulgaris. The Accure Laser System, manufactured by Quantas System, is the second laser device to be cleared for acne by the FDA, following the AviClear laser earlier this year. Acne is one of the hardest conditions to treat and according to recent studies, approximately 50 percent of women in their 20s, 33 percent of women in their 30s, and 25 percent of women in their 40s suffer from acne. 

The energy-based device targets sebaceous glands in the skin to stop the overproduction of oil leading to less breakouts. “Accure will be the second laser FDA approved for mild to severe inflammatory acne that uses 1726nm laser technology to selectively downregulate sebaceous glands,” explains Phoenix, AZ dermatologist Dr. Karan Lal. “Aviclear by Cutera was the first and has been out for a few months. As per reports, Accure has a technology that precisely controls thermal gradient depth which may limit side effects.”

Dr. Lal notes that Aviclear has been studied in all skin types and results show it is safe and bears a low risk of post-inflammatory hyperpigmentation, a concern with many heat-based devices for patients with skin of color. “The 1726nm wavelength is way more selective for sebum over melanin,” he says. “I think it’s great to have more safe technology when it comes to treating acne which is by far one of the most common skin-care complaints.”

Related Posts

Find a Doctor

Find a NewBeauty "Top Beauty Doctor" Near you

Give the Gift of Luxury

NewBeauty uses cookies for various reasons, including to analyze and improve its content and advertising. Please review our Privacy Policy and Terms of Use for more about how we use this data. By continuing to use this site, you agree to these policies.